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Dilated cardiomyopathy (DCM) is a devastating heart disease that
affects about 1 million people in the United States, but the
underlying mechanisms remain poorly understood. In this study,
we aimed to determine the biomechanical and structural causes of
DCM in transgenic mice carrying a novel mutation in the MYL2
gene, encoding the cardiac myosin regulatory light chain. Trans-
genic D94A (aspartic acid-to-alanine) mice were created and inves-
tigated by echocardiography and invasive hemodynamic and
molecular structural and functional assessments. Consistent with
the DCM phenotype, a significant reduction of the ejection frac-
tion (EF) was observed in ∼5- and ∼12-mo-old male and female
D94A lines compared with respective WT controls. Younger male
D94A mice showed a more pronounced left ventricular (LV) cham-
ber dilation compared with female counterparts, but both sexes of
D94A lines developed DCM by 12 mo of age. The hypocontractile
activity of D94A myosin motors resulted in the rightward shift of
the force–pCa dependence and decreased actin-activated myosin
ATPase activity. Consistent with a decreased Ca2+ sensitivity of
contractile force, a small-angle X-ray diffraction study, performed
in D94A fibers at submaximal Ca2+ concentrations, revealed repo-
sitioning of the D94A cross-bridge mass toward the thick-filament
backbone supporting the hypocontractile state of D94A myosin
motors. Our data suggest that structural perturbations at the level
of sarcomeres result in aberrant cardiomyocyte cytoarchitecture
and lead to LV chamber dilation and decreased EF, manifesting
in systolic dysfunction of D94A hearts. The D94A-induced devel-
opment of DCM in mice closely follows the clinical phenotype and
suggests that MYL2 may serve as a new therapeutic target for
dilated cardiomyopathy.
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Dilated cardiomyopathy (DCM) is a heart disease character-ized by left ventricular (LV) dilation, normal or reduced LV
wall thickness, interstitial fibrosis, and significantly diminished
contractile function (1). It is one of the most common cardio-
myopathies, with a predicted occurrence of 1 in 400 in the
United States (2). DCM may be sporadic and caused by ische-
mia, alcohol toxicity, or viral infection, or it can be genetic and
arise from mutated genes. Inherited gene defects account for up
to 25% of cases of DCM and include mutations in more than
40 different genes, including cytoskeletal, sarcomeric, sarco-
lemmal, and nuclear envelope proteins (3). In the family of
sarcomeric proteins, mutations in at least nine genes encoding
for myosin heavy chain (MHC), β-MHC (MYH7), α-MHC
(MYH6), MyBP-C (myosin-binding protein C), titin, cardiac ac-
tin, troponin (Tn) complex, and α-Tm (tropomyosin) proteins
are implicated in DCM (4). Recently, our group reported on a
mutation in MYL2, encoding the myosin regulatory light chain
(RLC), identified by exome sequencing in a pedigree with fa-
milial DCM (5). Biochemical studies of the recombinant aspartic
acid-to-alanine RLC mutant (D94A-RLC) showed that subtle
changes in the secondary structure of the RLC and its interaction
with the MHC resulted in chemomechanical uncoupling and
malfunction of D94A-mutated myosin motor protein (5).
Myosin RLC is a major regulatory subunit of striated-muscle
myosin and a modulator of Ca2+ and tropomyosin–troponin–con-
trolled regulation of cardiac muscle contraction (6). It is localized at
the head–rod junction of the MHC and, together with the myosin
essential light chain, stabilizes the α-helical neck region of the
myosin head, also called the lever arm (7). To address the mech-
anisms responsible for triggering abnormal function of D94A-RLC
myosin and cardiac defects consistent with DCM, we have gener-
ated transgenic (Tg) mice expressing the D94A-mutated human
ventricular RLC. Age- and sex-matched Tg-WT (wild-type) mice,
expressing human ventricular RLC and produced in this laboratory
previously (8), served as controls. The Tg-D94A animal model is a
clinically relevant rodent model of human familial DCM with a
mutation in myosin RLC encoded by MYL2 (5).
We provide strong evidence that the D94A mutation in car-
diac myosin RLC controls contractility via structural alterations
of myosin thick filaments and their interaction with the regulated
actin filaments triggering an aberrant cross-bridge cycling and
down-regulating myofilament response to Ca2+. These changes
ultimately result in significant reduction of the ejection fraction
(EF) and progressive dilated cardiomyopathy in D94A-mutated
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animals compared with respective WT-RLC control mice. Our
in-depth study clearly shows that the MYL2 variant, with the
D94A mutation in the myosin RLC, closely follows the clinical
DCM phenotype, providing a foundation for including theMYL2
gene in the pool of ∼40 currently screened DCM genes (3), and
that the myosin ventricular RLC may be considered an addi-
tional therapeutic protein target for DCM.
Results
Generation of the D94A-RLC Animal Model of DCM. To address the
mechanisms underlying cardiac dysfunction due to the D94A mu-
tation in myosin ventricular RLC protein (UniProtKB P10916), we
generated two lines (Ls) of the α-MHC–driven transgenic mice
expressing the D94A-mutated human ventricular RLC (Fig. 1A).
Female (F) and male (M) D94A-L1 and -L2 animals were used in
the experiments, and the results were compared with age- and
gender-matched Tg-WT-RLC mice (8). Direct assessment of the
human (%) versus mouse (%) cardiac RLC in the ventricles of WT
mice and in D94A-L1 and D94A-L2 by mass spectrometry showed
the expression of 87.6 ± 4.8 versus 12.4 ± 4.9 (WT), 53.4 ±
3.2 versus 46.6 ± 3.2 (L1), and 49.5 ± 2.8 versus 50.5 ± 2.8 (L2)
(Fig. 1B). Therefore, the generated model of DCM with ∼50% of
mutant RLC expression recapitulated the heterozygous trans-
mission of the mutated allele in a D94A-positive family (5). No
significant changes in RLC phosphorylation due to the D94A
mutation occurred in the hearts of mice, as tested by 2D SDS/
PAGE using mouse ventricular preparations (myosin and myofi-
brils) and RLC-specific antibodies (Fig. 1C). The latter result is
consistent with our in vitro study showing that the phosphorylation
of RLC by Ca2+/calmodulin-activated myosin light chain kinase was
not affected by D94A (5).
Ventricular Histology and Ultrastructure of D94A Hearts. Cardiac
phenotypes in Tg-D94A lines were identical and showed biven-
tricular cardiac dilation that was prominent by age ∼5 mo in
animals of both sexes, as evidenced by gross pathology images
and those of longitudinal heart sections of D94A compared with
WT mice (Fig. 2A). The myocardial ultrastructure assessed by
transmission electron microscopy in ∼9-mo-old D94A mice
revealed myopathic vacuolar formations in the myocardium of
A
B
C
Fig. 1. (A) Transgene construct with α-MHC promoter for expression of the D94A-RLC mutant (Left) and amino acid sequence of human cardiac RLC Uni-
ProtKB P10916 (pI 4.89; molecular mass 18.789 kDa) (Right). HGH, human growth hormone. (B) Relative expression of D94A-RLC in Tg mice. (B, Right) Sample
spectra of human (Upper) and mouse (Lower) RLC sequences. (C) Two-dimensional SDS/PAGE and Western blots of ventricular myosin fromWT, D94A-L1, and
D94A-L2 mouse lines. RLC proteins were visualized with the CT-1 antibody and the myosin essential light chain (ELC) protein (used as a loading control) with
the monoclonal ab680 antibody (Abcam). Phosphorylated and nonphosphorylated human (huRLC-WT and huRLC-D94A) and mouse (muRLC) RLC proteins
were separated according to their respective molecular masses and pI, and were quantitated using n = 5 or 6 myosin/myofibrillar preparations per line ±SD.
No statistical difference in RLC phosphorylation was observed between WT, D94A-L1, and D94A-L2 mice, P > 0.05, using one-way ANOVA.
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D94A versus WT mice and disrupted sarcomeric structures in
the mutant compared with age- and sex-matched WT-RLC mice
(Fig. 2B). Histopathology evaluation of left ventricular tissue from
∼5- and ∼12-mo-old D94A animals showed no obvious myofila-
ment disarray or fibrosis, and the rare fibrotic depositions occurred
in the hearts of older male but not female D94A mice (Fig. 2C).
The lack of fibrosis in D94A mice was confirmed by a quantitative
hydroxyproline (HOP) assay, which showed no difference in HOP
content in atria, interventricular septum, or LV tissue between
D94A lines and WT mice (Fig. 2D).
LV Chamber Dilation and Severely Reduced Ejection Fraction in D94A
Hearts. As heart chamber size increased, D94A mice developed
severely diminished cardiac function, as assessed by echocardiog-
raphy and invasive hemodynamics (9, 10) (Fig. 3). Consistent with
the DCM phenotype, a significant reduction of the ejection fraction
and fractional shortening occurred in younger and older D94A-
L1 and -L2 mice compared with respective WT controls (Table 1,
Table S1, and Movies S1 and S2). A largely dilated left ventricular
chamber (increased LVID) was observed in young male D94A
mice compared with female counterparts, but both sexes of D94A
lines developed progressive dilated cardiomyopathy by 12 mo of
age (Fig. 3A, Fig. S1, and Table S1).
Systolic Dysfunction in Young and Old D94A Mice. Hemodynamic
assessment and pressure–volume loop analysis of D94A versus WT
hearts showed significantly decreased intact heart function in both
age groups of D94A mice compared with respective WT mice (Fig.
3B and Movies S1 and S2). Older D94A mice demonstrated a more
pronounced phenotype compared with younger D94A mice, and
the diminished cardiac function was more severe in male than in
female D94A mice (Fig. S1 and Table S1). Decreased stroke work,
cardiac output, and prerecruitable stroke work in D94A versus WT
animals were paralleled by significantly elevated end-systolic and
end-diastolic volume) compared with respective WT mice (Fig. 3B,
Table 1, and Table S1).
In addition, D94A animals showed elevated values of Ea (ar-
terial elastance) compared with WT mice that were present in
young and old D94A mice of both sexes (Fig. 3B). Increased Ea is
a sympathetic response to compensate for reduced LV stroke
volume, which is controlled by the autonomic nervous system (11)
and may be responsible for the D94A-mediated reduction of
mechanical efficiency and the ventricular–arterial decoupling (12).
Our combined data indicate that young and old D94A mice of
both sexes clearly suffer from systolic dysfunction, and no di-
astolic disturbance (no changes in the relaxation constant; tau)
was observed in 5- or 12-mo-old F and M D94A mice compared
with respective WT controls (Fig. 3).
Abnormalities of Myofilament Contractility in Skinned and Intact
Papillary Muscle Fibers from D94A Mice. Skinned papillary muscle
strips isolated from 5-mo-old D94A mice demonstrated a de-
crease in the Ca2+ sensitivity of force, with ΔpCa50 ∼0.13 and ∼0.25
for D94Amice of both sexes compared with respectiveWT controls
(Fig. 4A and Table 2). No significant changes between genotypes
were observed in the ability of myosin to develop maximal con-
tractile force and, except for D94A-L1-F, no changes in maximal
tension at pCa 4 per cross-section of muscle were noted. A similar
trend of decreased Ca2+ sensitivity of force with no changes in Fmax
was observed in older animals (Fig. 4A and Table 2). Both age
groups of mice demonstrated a DCM characteristic rightward shift
in the force–pCa dependence and a significantly reduced
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Fig. 2. (A) Hearts of representative ∼5-mo-old male and female D94A mice and their longitudinal sections showing biventricular cardiac dilation compared
with respective WT controls. (Scale bars, 1 mm.) (B) Transmission electron microscopy images of ∼9-mo-old D94A-L1 vs. WT hearts. [Scale bars, 10 μm (Left),
2 μm (Middle), and 1 μm (Right).] Note excessive vacuolar formations in the myocardium of D94A vs. WT mice. (C) Hematoxylin and eosin- and Masson’s
trichrome-stained LV sections from ∼5- and ∼12-mo-old M and F D94A-L1 and -L2 vs. WT mice. (Scale bar, 100 μm.) (D) Hydroxyproline content in the hearts of
7- to 11-mo-old M and F D94A-L1 and -L2 compared with WT mice.
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Fig. 3. In vivo characterization of heart morphology and function in D94A vs. WT lines by echocardiography (A) and invasive hemodynamics (B). Two lines of
D94A (L1 and L2) female (open symbols) and male (closed symbols) were used and the results were compared with age- and sex-matchedWT mice. CO, cardiac
output; Ea, arterial elastance; EDV, end-diastolic volume; Ees, end-systolic elastance; EF, ejection fraction; FS, fractional shortening; LVID, left ventricular inner
diameter in diastole (d) and systole (s); PRSW, prerecruitable SW; SW, stroke work; Tau, relaxation time constant. The number of F and M mice examined is
given in Table 1. Data are the mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 D94A vs. WT, #P < 0.05, and ##P < 0.01 L1 vs. L2, by one-way ANOVA and
the post hoc Tukey’s multiple comparison test.
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contractile force at submaximal calcium concentrations (pCa 6 to
5). These data suggest that changes in the Ca2+-dependent actin–
myosin interactions trigger abnormal heart remodeling in D94A
mice and result in decompensated cardiac systolic function (low
EF) and dilated cardiomyopathy. Consistent with the D94A ef-
fects observed in this report, DCM-associated mutations in the thin-
filament proteins studied in mice (deletion mutation ΔK210 in
TNNT2) resulted in a diminished myofilament Ca2+ sensitivity with no
changes in maximal contractile force (13).
We also investigated whether the changes in the force–pCa re-
lationship observed in D94A mice originated from cellular calcium
dysregulation or from abnormal myosin motor activity or other
sarcomeric dysfunction. Force and calcium transients were mea-
sured in intact papillary muscle fibers from 6- to 8-mo-old D94A
mice and age- and sex-matched WT mice using the IonOptix Cal-
cium and Contractility Recording System (Fig. 4B). Electrically
stimulated isometric twitches were recorded simultaneously with
[Ca2+] transients after 1.5-h incubation with Fura-2 AM. No dif-
ferences in peak force were found between the genotypes (Fig. 4B)
but, consistent with the decreased myofilament Ca2+ sensitivity in
skinned fibers, the relaxation phase of force transients was signifi-
cantly faster (shorter time) in D94A compared with WT muscles
(67 vs. 98 ms). No changes in intracellular [Ca2+] transients were
observed (Fig. 4B). These data led us to the conclusion that the
contractile properties of D94A-mutated myosin cross-bridges and
their altered interaction with the thin filaments are most likely re-
sponsible for development of DCM in D94A animals.
Consistent with the lack of changes in myocellular calcium ho-
meostasis, the gene expression profiles of the major intracellular
players of the excitation–contraction coupling revealed no differences
between D94A and WT hearts, and no differences were also noted
between male and female mice (Fig. 4C). Total mRNA was isolated
from the ventricles of three male and three female 5- to 6-mo-old
D94A-L1 and from WT control mice. No D94A-mediated changes
Table 1. Intact heart function in ∼5-mo-old D94A-RLC mice compared with WT-RLC animals by echocardiography and
invasive hemodynamics
Parameter D94A-L1-F D94A-L2-F WT-F D94A-L1-M D94A-L2-M WT-M
Echocardiography
No. of animals 14 6 8 9 6 10
Heart/body, mg/g 4.63 ± 0.16 4.52 ± 0.36 4.48 ± 0.29 4.66 ± 0.12 5.15 ± 0.14 5.31 ± 0.21
Heart/tibia, mg/mm 7.01 ± 0.2 6.8 ± 0.19 6.69 ± 0.55 9.06 ± 0.27 10.34 ± 0.35* 8.74 ± 0.3a
HR, bpm 503 ± 9 498 ± 17 478 ± 17 512 ± 15 520 ± 11 497 ± 14
IVCT, ms 15.09 ± 1.01 12.48 ± 1.72 15.33 ± 1.6 15.49 ± 1.41 11.61 ± 1.11 15.09 ± 1.6
IVRT, ms 17.06 ± 1.5 14.92 ± 1.42 15.85 ± 0.9 15.76 ± 1.59 13.94 ± 0.46 14 ± 0.69
MV E/A 2.63 ± 0.24 1.83 ± 0.23 2.4 ± 0.29 1.88 ± 0.19 1.74 ± 0.17 1.91 ± 0.13
MV E/E′ −26.7 ± 2.4 −24.2 ± 2.8 −25.9 ± 2.0 −22.1 ± 1.3 −31.2 ± 2.1 −25.5 ± 2.4
EF, % 47 ± 2** 52 ± 1 60 ± 3 35 ± 2***,#,a 45 ± 2**,a 60 ± 2
FS, % 23 ± 1* 22 ± 2* 31 ± 3 19 ± 1a,** 23 ± 1 29 ± 2
IVS;d, mm 0.81 ± 0.03 0.76 ± 0.03 0.74 ± 0.03 0.82 ± 0.06 0.87 ± 0.03 0.9 ± 0.04a
IVS;s, mm 1.09 ± 0.04 0.98 ± 0.06 1.09 ± 0.08 1.11 ± 0.09 1.13 ± 0.05 1.21 ± 0.08
LVID;d, mm 4.05 ± 0.11 3.97 ± 0.09 3.89 ± 0.08 4.19 ± 0.12 4.42 ± 0.08a 4.16 ± 0.1a
LVID;s, mm 3.12 ± 0.12* 3.09 ± 0.09 2.66 ± 0.14 3.38 ± 0.13* 3.39 ± 0.10* 2.96 ± 0.13
LVPW;d, mm 0.7 ± 0.03 0.71 ± 0.03 0.73 ± 0.02 0.8 ± 0.05 0.77 ± 0.04 0.78 ± 0.02
LVPW;s, mm 0.9 ± 0.05* 0.96 ± 0.05 1.06 ± 0.06 0.99 ± 0.06 1.06 ± 0.07 1.14 ± 0.04
Hemodynamics
No. of animals 10 6 5 6 5 6
SW, mmHg×μL 1,779 ± 144 1,898 ± 137 1,896 ± 127 1,741 ± 259 2,592 ± 153a 2,577 ± 344
CO, μL/min 11,349 ± 1,155 13,330 ± 753 12,538 ± 1,109 11,106 ± 1,138* 16,938 ± 916a 16,673 ± 1,777
SV, μL 23.24 ± 2.06 24.99 ± 1.14 24.92 ± 1.11 21.78 ± 1.87*,# 31.54 ± 1.57a 32.86 ± 2.89a
ESV, μL 31.92 ± 3.46 30.65 ± 1.91 23.6 ± 2.26 45.95 ± 2.56*,a 41.22 ± 1.94a 34.31 ± 3.66a
EDV, μL 49.25 ± 4.09 50.39 ± 2.65 44.02 ± 1.8 62.49 ± 3.51 67.98 ± 2.35a 59.35 ± 4.49a
Pes, mmHg 100.2 ± 3.03* 97.31 ± 3.78 87.13 ± 3.21 99.6 ± 4.96 95.23 ± 1.59 92.23 ± 3.61
Ped, mmHg 5.48 ± 0.78 7.22 ± 2.29 5.42 ± 1.42 5.42 ± 1.09 4.91 ± 1.72 7.29 ± 1.8
HR, bpm 484 ± 16 532 ± 8 499 ± 25 506 ± 20 537 ± 12 504 ± 13
Ea, mmHg/μL 4.54 ± 0.28* 3.94 ± 0.21 3.53 ± 0.14 4.75 ± 0.48** 3.02 ± 0.17 2.93 ± 0.3
Ea/Ees 1.73 ± 0.22 1.99 ± 0.56 0.84 ± 0.08 1.36 ± 0.25 0.96 ± 0.25 1.42 ± 0.24
dP/dtmax, mmHg/s 9,339 ± 787 11,099 ± 1,794 9,249 ± 574 8,818 ± 659 9,010 ± 544 8,248 ± 575
dP/dtmin, mmHg/s −9,428 ± 516 −9,593 ± 1,162 −9,133 ± 405 −8,496 ± 791 −9,655 ± 622 −8,784 ± 1,051
Tau, ms 6.22 ± 0.18 6.51 ± 0.82 5.87 ± 0.29 6.44 ± 0.23 5.46 ± 0.22 6.86 ± 1.18
No. of animals 9 4 5 6 5 5
ESPVR 3.24 ± 0.47 2.9 ± 0.76 4.24 ± 0.38 3.99 ± 0.81 4.39 ± 1.4 2.35 ± 0.52
EDPVR 0.15 ± 0.02 0.14 ± 0.02 0.16 ± 0.03 0.15 ± 0.06 0.10 ± 0.02 0.10 ± 0.01
PRSW 52.53 ± 4.59 58.09 ± 6.02 70.64 ± 5.78 60.69 ± 2.6 75.14 ± 6.35 68.64 ± 5.84
dP/dtmax-EDV 184.62 ± 21.3 184.78 ± 35.6 150.1 ± 19.66 172.61 ± 24.6 144.58 ± 15.8 117.44 ± 19.1
Heart weight/body weight (in mg/g); heart weight/tibia length (in mg/mm); CO, cardiac output; d, diastolic; dP/dtmax, peak rate for pressure
rise; −dP/dtmin, peak rate for pressure decline; EDPVR, slope of end-diastolic PV relationship; EDV, end-diastolic volume; Ees, end-systolic
elastance, slope of ESPVR (end-systolic pressure–volume relationship); ESV, end-systolic volume; FS, fractional shortening; HR, heart rate (in
beats per min); IVCT, isovolumetric contraction time; IVRT, isovolumetric relaxation time; IVS, interventricular septum; LVID, left ventricular
inner diameter; LVPW, LV posterior wall; MV E/A, mitral early (E)-to-late (A) diastolic inflow velocity; E’, early diastolic velocity; Ped, end-
diastolic pressure; Pes, end-systolic pressure; PRSW, prerecruitable SW (slope of SW–EDV relationship); s, systolic; SV, stroke volume; SW, stroke
work; Tau, relaxation time constant. Data are the mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 D94A vs. WT, #P < 0.05 L1 vs. L2, by one-
way ANOVA and the post hoc Tukey’s multiple comparison test; aP < 0.05 M vs. F, by Student’s t test.
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in the expression of voltage-dependent L-type calcium channel,
alpha-1C (Ca2+ channel), sodium–calcium exchanger, cardiac rya-
nodine receptor (Ryr2), ATP2a2 (SERCA2), and phospholamban
genes were observed compared withWT control hearts (Fig. 4C). No
changes in myh7 between genotypes were noted but, in agreement
with reports on DCM patients (14), mRNA ofmyh6 was significantly
down-regulated in D94A animals (Fig. 4C). In addition, ANF and
BNP, stress response genes, were slightly up-regulated in D94A-F
compared with WT-F mice, but the difference between genotypes
did not reach statistical significance (Fig. 4C).
Hypocontractility of D94A-RLC Myosin. To understand the effect of
D94A on myosin motor function, actin-activated ATPase activity
assays were conducted on cardiac myosin purified from ventricles
of D94A and WT mice. Consistent with other DCM mutations in
α-MHC motor proteins studied in mice (15), a significantly lower
Vmax was observed for D94A compared with WTmyosin (Fig. 5A),
suggesting a slower transition from the weakly (A·M·ATP ↔
A·M·ADP·Pi) to strongly (A·M·ADP↔ A·M) bound D94A cross-
bridges. No differences in the Michaelis–Menten constant (Km)
were noted between the groups. Significantly, this hypocontractile
activity of D94A-mutated myosin motors reflects a diminished
ability of myosin to hydrolyze ATP to produce energy for muscle
contraction (Fig. 5A).
Fluorescence-based steady-state binding of D94A-myosin to
pyrene-labeled F-actin under rigor (no ATP) conditions supports
the ATPase data and shows a stronger interaction of myosin with
actin for the mutant, suggesting slower myosin dissociation rates
(Fig. 5B). Lower Vmax of D94A-myosin could also be due to
fewer myosin heads participating in the contractile cycle, and
both scenarios indicate a mutation-induced hypocontractility of
the myosin motor and a compromised chemomechanical cycle
that contracts the sarcomere, leading to lower EF and systolic
dysfunction in the D94A mouse model of DCM.
Small-Angle X-Ray Diffraction Patterns in D94A and WT Papillary
Muscles. The interfilament lattice spacing (d1,0) can be used to
derive the center-to-center distance between two adjacent thick
and thin filaments. The intensity ratio (I1,1/I1,0) is the ratio of the
integrated intensity of the 1,1 equatorial reflection (representing
density in the plane containing both thick and thin filaments) to
that of the 1,0 equatorial reflection (reflecting density in the
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Force 
transients 
1L-A49DTW
Male 
(n=3) 
Female 
(n=3) 
All 
(n=6) 
Male 
(n=5) 
Female 
(n=3) 
All 
(n=8) 
Peak force 
(mN/mm2) 0.63±0.31 0.55±0.56 0.59±0.36 1.32±0.66 0.92±0.51 1.19±0.60
TF-contract (ms) 70±22 75±7 73±15 75±11 67±5 72±10 
TF-relax (ms) 89±23 104±39 98±31 72±20 58±15 67±19* 
VF-contract (s-1) 3.1±1.3 6.37±9.2 4.72±6.1 7.82±6.3 4.84±3.9 6.70±5.4 
VF-relax (s-1) 2.2±1.2 3.6±5.3 2.9±3.5 8.3±6.8 3.8±2.4 6.6±5.8 
12 months
Calcium 
transients 
1L-A49DTW
Male 
(n=3) 
Female 
(n=3) 
All 
(n=6) 
Male 
(n=5) 
Female 
(n=3) 
All 
(n=8) 
TC-contract (ms) 14±4 28±15 21±13 20±7 17±3 19±6 
TC-relax (ms) 161±23 122±21 141±29 104±22 132±7 114±22 
VC-contract (s-1) 5.86±2.2 3.82±2.0 4.84±2.2 4.06±2.31 9.10±3.6 5.95±3.7 
VC-relax (s-1) 0.50±0.16 1.18±1.4 0.84±0.94 0.77±0.29 1.30±0.73 0.97±0.52
Fig. 4. (A) Contractile function in papillary muscle fibers from ∼5- and ∼12-mo-old D94A-L1 and -L2 vs. WT mice. Open symbols depict female and closed
symbols indicate male animals. (B) The effect of D94A mutation on force and calcium transients in intact papillary muscles. The measurements were per-
formed on intact papillary muscles from 6- to 8-mo-old gender-matched D94A-L1 (five M and three F) and WT (three M and three F) mice. Time (in milli-
seconds) to depart 50% (t50) from t0 to peak during contraction, and from peak to baseline during relaxation, is characterized by TF-contract and TF-relax
(force transients) and TC-contract and TC-relax ([Ca
2+] transients). Maximum velocity of force departing from and returning to the baseline during muscle
contraction and relaxation is reported as VF-contract and VF-relax (force transients) and VC-contract and VC-relax ([Ca
2+] transients). Note a significant (*P <
0.05) decrease in TF-relax in D94A-L1 vs. WT fibers. Results are presented as the average ± SD of n animals with *P < 0.05 and **P ≤ 0.01 for mutant vs. WT and
#P < 0.05 for D94A-L1 vs. D94A-L2, using one-way ANOVA (A) or Student’s t test (B). (C) Gene expression profiles in D94A and WT mice. Real-time qPCR was
performed on three F (open symbols) and three M (close symbols) D94A-L1 and WT mice, and the results are presented as fold change in transcript expression
in D94A vs. WT mice. Data are the mean ± SEM. *P < 0.05, using one-way ANOVA with the Tukey’s multiple comparison test.
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plane containing only thick filaments) (16). Both parameters
(d1,0 and I1,1/I1,0) are important metrics of sarcomeric structure
that were previously shown to be sensitive to amino acid sub-
stitutions in any of the sarcomeric components (10, 17).
The equatorial X-ray patterns were collected simultaneously with
the measurements of force at pCa 8 to 4 on skinned papillary
muscles from D94A versus WT mice at sarcomere length 2.1 μm
(10). While no changes due to the D94A mutation were found in
d1,0 (in nm), there was a significant decrease in I1,1/I1,0 ratio upon
fiber activation (Fig. 6). The smaller I1,1/I1,0 in DCM versus WT
mice indicates repositioning of the D94A-myosin cross-bridge mass
closer to the thick-filament backbone (10, 17). We propose that this
reduced I1,1/I1,0 ratio in D94A mice reflects less association of the
myosin heads with the thin filaments and underlies the key structural
change in the sarcomere that results in desensitization of myofila-
ments to Ca2+. Consistent with this line of thinking, a significantly
reduced Ca2+ sensitivity of force was measured in skinned papillary
muscle fibers from D94A mutant versus WT mice (Fig. 4A). On the
other hand, in accordance with no changes in maximal force de-
veloped by D94A muscle fibers (Fig. 4 A and B), no changes in the
interfilament lattice spacing, d1,0, was measured upon activation (at
pCa 5.2) in D94A mice compared with WT (Fig. 6).
Discussion
Dilated cardiomyopathy is a severe pathology of the heart that
can appear as a spectrum of symptoms, from subtle to severe,
including congestive heart failure. Reduced contractile function
and pathological remodeling of the heart are recognized clinical
hallmarks of DCM, but the early molecular events that impair
heart performance are unknown and require further in-
vestigation. Consistent with DCM characteristics in human pa-
tients carrying the D94A mutation in MYL2 (5), the D94A
transgenic mouse model presents with ventricular chamber di-
lation, which is accompanied by a decreased ejection fraction
and mild global left ventricular systolic dysfunction (Fig. 3).
Although the histologic alterations include interstitial and re-
placement fibrosis, D94A animals do not demonstrate excessive
fibrotic lesions and only mild fibrosis is observed in older D94A
male hearts (Fig. 2). This result is consistent with findings of
other studies on small or large animal models of DCM sug-
gesting that myocyte hypertrophy and fibrosis are not prominent
features in this form of cardiomyopathy despite changes in he-
modynamics and LV chamber structure and function (15, 18).
In addition to occurrences of fibrosis in male and not female
D94A hearts (Fig. 2), the diminished cardiac function was also
observed to be more severe in male than in female D94A mice
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Fig. 5. (A) Actin-activated myosin ATPase activity of D94A and WT myosins. A significantly lower Vmax was observed for D94A-L1 (0.57 ± 0.02 s
−1; n = 14) and
D94A-L2 (0.69 ± 0.03 s−1; n = 6) myosins compared with WT (0.88 ± 0.05 s−1; n = 8). (B) Fluorescence-based binding assays of D94A or WT myosin to pyrene-
labeled F-actin in the absence of ATP (rigor). Note a significantly higher binding affinity of D94A-L1 (Kd 4.48 ± 0.67 nM; n = 9) and D94A-L2 myosin (Kd 5.73 ±
0.58 nM; n = 10) vs. WT (Kd 8.31 ± 0.35 nM; n = 10) control. Both assays (A and B) were performed on myosin purified from left and right ventricles of 5- to
8-mo-old F and M D94A and WT mice. Approximately four or five hearts per group were used to generate one batch of myosin, and the assays were repeated
with two to four different batches of myosin. No differences between the sexes were noted, and the data from M and F mice were pooled. Data are the
mean ± SEM of n experiments with *P < 0.05, **P < 0.01, and ***P < 0.001 calculated, using one-way ANOVA with the Tukey’s multiple comparison test.
Table 2. Contractile function in skinned papillary muscle fibers from ∼5- and ∼12-mo-old D94A-RLC mice compared with WT-RLC
animals
Parameter D94A-L1-F D94A-L2-F WT-F D94A-L1-M D94A-L2-M WT-M D94A-L1ALL D94A-L2ALL WTALL
Five-mo-old mice
No. of animals
(fibers)
5 (40) 5 (46) 5 (39) 5 (38) 5 (39) 5 (49) 10 (78) 10 (85) 10 (88)
Fmax, kN/m
2 57.71 ± 1.36*,# 54.1 ± 2.98 54.27 ± 0.32 55.19 ± 1.18 54.94 ± 3.14 53.99 ± 1.76 56.45 ± 1.79 54.52 ± 2.92 54.13 ± 1.2
pCa50 5.56 ± 0.08 5.54 ± 0.05* 5.67 ± 0.09 5.52 ± 0.06**
,# 5.44 ± 0.01** 5.69 ± 0.07 5.54 ± 0.07** 5.49 ± 0.06** 5.68 ± 0.07
Hill coefficient 2.99 ± 0.68 3.61 ± 0.88 2.81 ± 0.29 2.8 ± 0.82 2.89 ± 0.61 3.25 ± 0.78 2.89 ± 0.72 3.25 ± 0.81 3.03 ± 0.6
Twelve-mo-old
mice
No. of animals
(fibers)
5 (44) 3 (18) 5 (46) 5 (44) 4 (19) 4 (51) 11 (88) 7 (37) 9 (97)
Fmax, kN/m
2 56.06 ± 1.47* 57.62 ± 1.22* 52.51 ± 2.45 55.89 ± 1.07 56.39 ± 0.35 54.38 ± 1.54 55.97 ± 1.2* 56.91 ± 0.99* 53.34 ± 2.21
pCa50 5.55 ± 0.05 5.56 ± 0.01 5.66 ± 0.1 5.58 ± 0.06 5.56 ± 0.04 5.61 ± 0.05 5.57 ± 0.05* 5.56 ± 0.03* 5.64 ± 0.08
Hill coefficient 3.78 ± 0.35**,## 2.84 ± 0.25 2.65 ± 0.19 3.8 ± 0.29**,## 2.97 ± 0.45 2.71 ± 0.21 3.79 ± 0.3**,## 2.91 ± 0.36 2.68 ± 0.19
Fmax, tension per cross-section of muscle; pCa50, calcium concentration for half-maximal activation (Ca
2+ sensitivity). Data are the mean ± SD of n (number of animals) experiments;
*P < 0.05 and **P ≤ 0.01 for mutant vs. WT, and #P < 0.05 and ##P ≤ 0.01 for D94A-L1 vs. D94A-L2, using one-way ANOVA.
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(Fig. 3). A recent study has shown that in all cardiomyopathy
subtypes there was an unequal sex distribution, with a tendency
toward men for DCM, HCM (hypertrophic cardiomyopathy),
and ARVC (arrhythmogenic right ventricular cardiomyopathy)
and toward women for RCM (restrictive cardiomyopathy) (19).
Reports also show that under disease conditions, females have
higher expression of genes related to energy metabolism and can
better maintain their metabolic function in response to a disease
stimulus than males (20). Furthermore, significant sex differ-
ences in genes involved in the regulation of fibrosis and in-
flammation with a significant repression of these processes in
women were also reported (21), indicating that females may be
protected against effects of fibrosis and inflammation.
Previous studies have implicated different cytoskeletal and sar-
comeric proteins in familial DCM, but the mechanisms by which
these divergent mutations cause disease range from impairment of
force transduction (22, 23) and disturbance of myocellular Ca2+ (24)
to direct effects of sarcomeric protein mutations on myofilament
Ca2+ sensitivity and contractile force generation, leading to systolic
dysfunction and DCM (25). Creation of genetically altered trans-
genic and knockin mice expressing mutant proteins in their hearts
provides valuable animal models to study the molecular mechanisms
of DCM pathogenesis (13, 15, 26–29). Consistent with our results,
mouse models of two MYH7 mutations (S532P and F764L) in an
α-MHC background displayed depressed contractile function in
isolated cardiomyocytes and a reduced ability of mutant myosins to
translocate actin (Vactin) but had similar force-generating capacities
(15). Thin-filament mouse models of DCM carrying disease-causing
mutations in α-Tm (28) or troponin subunits (13, 29) demonstrated
a largely reduced Ca2+ sensitivity and thus caused impairment of
cardiac function through a malfunction of the Tm–Tn regulatory
system. On the other hand, a knockin mouse model of DCM
expressing a truncated form of MyBP-C (26) exhibited neonatal
onset of a progressive DCM with myofibrillar disarray, fibrosis, and
dystrophic calcification, but increased oxidative stress and myocar-
dial inflammation were thought to underlie the diminished con-
tractile response and heart failure in these mice (27, 30).
Small-angle X-ray diffraction patterns in skinned papillary
muscles from D94A mice revealed distinct structural abnormali-
ties in the sarcomeres of mouse hearts that may explain the un-
derlying DCM phenotype. We demonstrate here that structural
consequences of the D94A mutation in myosin RLC (Fig. 6)
closely correlate with the functional abnormalities in D94A pap-
illary muscle fibers (Table 2) and with abnormal heart function in
echocardiography and invasive hemodynamics experiments (Table
1). The ability of D94A-mutated myosin to generate contractile
force in skinned papillary muscle fibers at a level comparable to
WT mice (Fig. 4A) correlated well with no changes in the inter-
filament lattice spacing (d1,0) measured in D94A and WT fibers
(Fig. 6). On the other hand, consistent with the reduced Ca2+
sensitivity of force observed in D94A fibers (Fig. 4A), a statistically
significant decrease in I1,1/I1,0 ratio was measured in D94A fibers
upon submaximal activation compared with WT (Fig. 6). A de-
crease in I1,1/I1,0 represents less association of the myosin heads
with the thin filaments, which could explain the rightward shift in
the force–pCa relationship in D94A versus WT fibers. Therefore,
the structural changes in the D94A-RLC–mutated myosin motors
stabilized their hypocontractile conformation (31) and led to de-
sensitization of the myofilaments to calcium during force gener-
ation. These changes ultimately resulted in reduced ejection
fraction and systolic abnormalities in D94A hearts.
The molecular pathogenesis of dilated cardiomyopathy was
recently assessed in the context of the myosin superrelaxed state
and interacting-heads motif (IHM) paradigm (31). Similar to the
effects seen in this report (Fig. 5A and Table 2), DCM-causing
mutations in MYH7 were shown to have modest effects on IHM
interactions but have substantially reduced MHC motor func-
tions, particularly nucleotide binding, resulting in reduced ATP
consumption and decreased contractility. The authors elegantly
demonstrated that genetic DCM and HCM variants differen-
tially impact myosin motor functions and specific IHM interac-
tions explaining the mechanisms for diminished contractile
power in DCM and the distinctly compromised relaxation and
energetics in HCM (31). Our data suggest that the D94A-RLC
mouse model may be highly suitable for testing of novel myosin-
specific therapeutics for systolic heart dysfunction, for example,
omecamtiv mecarbil, aimed at increasing cardiac myosin acti-
vation and the duration of ejection without changing car-
diomyocyte calcium homeostasis (32).
The results of this study strongly suggest that mice carrying the
D94A-RLC mutation develop dilated cardiomyopathy by a
mechanism involving direct effects of D94A on cardiac myosin,
the molecular motor of the heart that transduces chemical energy
from ATP hydrolysis into mechanical energy to drive cardiac
1,01,0
1,11,1
1,01,0 1,11,1
WT No fibers D94A-L1 No fibers P-value 
Intensities ratio (I1,1/I1,0)
pCa 8  
(Relaxation) 0.22±0.06 15 (7F, 8M) 0.26±0.08 15 (8F, 7M) 0.206 
pCa 5.2 
(Activation) 0.43±0.02 14 (7F, 7M) 0.35±0.03* 12 (4F, 8M) 0.043 
Lattice spacing (d1,0 in nm)
pCa 8  
(Relaxation) 41.54±0.3 16 (8F, 8M) 41.38±0.24 15 (8F, 7M) 0.722 
pCa 5.2 
(Activation) 41.45±0.31 15 (7F, 8M) 41.64±0.29 14 (7F, 7M) 0.701 
Fig. 6. Small-angle X-ray diffraction patterns and integrated intensity
traces collected from papillary muscles from D94A-L1 (n = 3 F and 3 M mice)
vs. WT (n = 4 F and 3 M mice) in relaxation (pCa 8) and activation (pCa 5.2).
All patterns show clearly resolved 1,0 and 1,1 reflections. Note the significant
difference in I1,1/I1,0 between D94A-L1 and WT (P = 0.043). Data are the
mean ± SEM of n animals with *P < 0.05, using Student’s t test.
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muscle contraction and support heart pump function to meet
body demands for blood. Supporting this notion, the gene ex-
pression profiles of the major players in excitation–contraction
coupling showed no differences between D94A and WT hearts
(Fig. 4C). Studies on animal models of cardiomyopathy and human
heart failure samples argue that dysregulation of RLC phosphory-
lation plays a role in the manifestation of the disease phenotype
(10, 33, 34). However, in our previous in vitro study (5), as well as in
this report, the D94A mutation did not reduce the overall RLC
phosphorylation in the mutant myocardium compared with WT
mice (Fig. 1C). Perhaps, as proposed by the Ferenczi group (35),
the steady-state level of RLC phosphorylation in D94A mice may
signify a compensatory adaptation to DCM pathology.
To conclude, D94A-mediated DCM is a rather complex issue,
but clearly involves abnormal interactions between the hypocon-
tractile myosin motors and actin–Tm–Tn filaments. The structural
perturbations located at the level of sarcomeres result in aberrant
cardiomyocyte cytoarchitecture leading to LV chamber dilation
and decreased ejection fraction manifesting in systolic dysfunction
of D94A hearts. Our comprehensive study demonstrates that this
novel DCMMYL2 variant with the D94A mutation in the myosin
RLC follows the clinical DCM phenotype, and suggests that in
addition to other sarcomeric genes, MYL2 may serve as a thera-
peutic target for dilated cardiomyopathy disease.
Materials and Methods
Detailed materials and methods are outlined in SI Materials and Methods
This study conforms to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (36). All protocols
were approved by the Institutional Animal Care and Use Committee at the
University of Miami Miller School of Medicine (assurance number A-3224-01,
effective November 24, 2015). Euthanasia of mice was achieved through
inhalation of CO2 followed by cervical dislocation.
Generation of Transgenic DCM D94A-RLC Mice. The cDNA of human D94A-
mutated ventricular RLC [National Center for Biotechnology Information
(NCBI) accession no. NP_000423.2] was inserted downstream of the α-MHC
promoter (clone 26, provided by Jeffrey Robbins, Cincinnati Children’s Hos-
pital Medical Center, Cincinnati, OH), and two Tg lines (D94A-L1 and D94A-
L2) expressing mutated human RLC in mice were produced as described
previously (8). The results were compared with previously produced Tg-WT
mice expressing nonmutated human ventricular RLC (8). Relative expression
of D94A mutant RLC in Tg lines was assessed by mass spectrometry (MS). SDS/
PAGE bands of mouse purified myosin from four or five hearts per group
were digested with trypsin and then reduced and alkylated. Digested pep-
tides were analyzed by MS, and protein identification was determined using
X! Tandem (9). Relative amounts of human versus mouse protein were de-
termined by the ratio of the number of human-specific peptides (AGGANSN
or EEVDQM) or mouse-specific peptides (IEGGSSN or EEIDQM) for which the
most identified spectra were obtained (9, 37).
Heart Morphology and Function in D94A and WT Animals. Histopathology ex-
amination of paraffin-embedded longitudinal sections of whole mouse hearts
stained with hematoxylin and eosin and Masson’s trichrome, and the electron
microscopy evaluation of myocardial ultrastructure, was assessed as described
earlier (9, 10). Heart morphology and function were examined in male and
female ∼5- and ∼12-mo-old D94A mouse lines (L1 and L2) and compared with
age- and gender-matched WT mice by echocardiography and invasive he-
modynamic assessments as outlined in detail in Yuan et al. (9, 10).
Myosin Cross-Bridge Contractile and Structural Properties in Skinned and Intact
Fibers from D94A Versus WT Mice. Binding of D94A mouse purified myosin to
pyrene–actin and actin-activated myosin ATPase activity assays were per-
formed as previously reported (9, 10). Steady-state force development and
force–pCa measurements were performed on skinned papillary muscle fibers
with sarcomere length adjusted to 2.1 μm, according to previously described
protocols (9). Approximately 5- and 12-mo-old D94A-L1 and -L2 animals were
used with each heart, yielding on average 8 to 10 individual muscle strips.
Force and [Ca2+] transient measurements were performed on intact papillary
muscles from 6- to 8-mo-old sex-matched D94A-L1 (five M and three F) and
WT (three M and three F) mice using the IonOptix Calcium and Contractility
Recording System. Intact muscle fibers were stimulated at 1 Hz, and force and
fluorescence (340/380 nm ratio) transients were recorded (8). The equatorial
X-ray patterns were collected simultaneously with the measurements of force
at pCa 8 to 4 on skinned papillary muscles from D94A-L1 (three F and three M)
versus WT-RLC (four F and three M) mice at sarcomere length 2.1 μm (10).
Statistical Analysis. All values are shown as means ± SD or means ± SEM.
Statistically significant differences between two groups were determined
using an unpaired Student’s t test, with significance defined as *P < 0.05,
**P < 0.01, and ***P < 0.001. Comparisons between multiple groups were
performed using one-way ANOVA and the Tukey’s multiple comparison test.
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